New Gene-Targeting drug could change how we treat high blood pressure
NCT ID NCT06205628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called ADX-850 in 28 people with mild to moderate high blood pressure. The drug uses siRNA technology to target genes involved in blood pressure regulation. The main goal is to check safety and how the drug moves through the body, with a secondary look at its effect on blood pressure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ADX-850 (siRNA drug)
What this could lead to
If successful, this could lead to a new treatment option for high blood pressure that may require less frequent dosing.
What could go wrong
This is an early Phase 1 study with only 28 participants, so safety and effectiveness are not yet proven. The drug may not lower blood pressure enough or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMAX Clinical Research
Adelaide, South Australia, 5000, Australia
-
Clinitrials Pty Ltd
Perth, Australia
-
Linear Clinical Research
Nedlands, Western Australia, 6009, Australia